Table 1:
Baseline Characteristics in FOURIER Trial
| Evolocumab N=13,784 |
Placebo N=13,780 |
|
|---|---|---|
| Demographics | ||
| Age, yr (±SD) | 62.5 (9.1) | 62.5 (8.9) |
| Male | 10,397 (75) | 10,398 (76) |
| White | 11,748 (85) | 11,710 (85) |
| Obese (BMI >30) | 5,419 (39) | 5,523 (40) |
| Medical History | ||
| Myocardial infarction | 11,145 (81) | 11,206 (81) |
| Ischemic stroke | 2,686 (20) | 2,651 (19) |
| Peripheral artery disease | 1,858 (14) | 1,784 (13) |
| Heart Failure | 3224 (23) | 3170 (23) |
| Hypertension | 11,045 (80) | 11,039 (80) |
| Diabetes mellitus | 5,054 (37) | 5,027 (37) |
| Current cigarette use | 3,854 (28) | 3,923 (29) |
| Hormone Replacement Therapy | 518 (3.8) | 520 (3.8) |
| Median Lab Measures (IQR) | ||
| LDL cholesterol — mg/dl | 92 (80–109) | 92 (80–109) |
| Total cholesterol — mg/dl | 168 (151–188) | 168 (151–189) |
| HDL cholesterol — mg/dl | 44 (37–53) | 44 (37–53) |
| Triglycerides — mg/dl | 134 (101–183) | 133 (99–181) |
| Lipoprotein (a) — nmol/L | 37 (13–166) | 37 (13–164) |
Data shown are n(%) unless otherwise indicated.
BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; IQR, interquartile range; SD, standard deviation; Yr, years.